Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 in advanced non-small-cell lung cancer
NCT02182050Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2005
- Primary completion
- Jan 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Aug 2005; status: completed.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02182050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182050.